Nan Wang1, Xiao-Hong Lu1, Susana V Sandoval1, X William Yang1. 1. Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, and Brain Research Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Abstract
BACKGROUND: C2-8 is a small molecule inhibitor of polyglutamine aggregation and can reduce photoreceptor neurodegeneration in a Drosophila model of Huntington's disease (HD). Further preclinical studies have shown that oral administration of C2-8 in R6/2 HD transgenic mice can penetrate into the brain, reduce mHTT-exon1 aggregation, improve motor performance and diminish striatal neuron atrophy. OBJECTIVE: In this independent preclinical study, we aimed to evaluate the pharmacokinetic properties and therapeutic efficacy of C2-8 intraperitoneal (IP) delivery in the R6/2 HD mouse. METHODS: R6/2 mice were IP injected with low dose C2-8 (10 mg/kg), high dose C2-8 (20 mg/kg), or vehicle twice daily from 3 weeks to 3 months old. Longitudinal behavioral tests (accelerating Rotarod and wire-hang) were performed to evaluate the motor deficits, and neuropathology was measured by unbiased stereology. RESULTS: We confirmed that the compound has good blood-brain-barrier penetration after acute or sub-chronic intraperitoneal delivery. Chronic treatment with C2-8 in R6/2 mice results in a significant reduction of nuclear mHTT aggregate volume in the brains, replicating a key finding of C2-8 as a polyglutamine aggregation inhibitor in vivo. However, by comparing HD mice with C2-8 treatment to those with vehicle treatment, we were unable to demonstrate significant amelioration of motor deficits using Rotarod and wire-hang tests. Moreover, we did not observe improvement in the striatal neurodegenerative pathology, as measured by brain weight, striatal volume, and striatal neuron volume in the C2-8 treated R6/2 mice. CONCLUSIONS: Our study supports the practice of independent preclinical studies for novel molecules in HD therapeutic development and suggests that the use of alternative delivery strategies and full-length HD mouse models are likely needed to further assess whether the aggregate-inhibiting properties of C2-8 can be consistently translated into a preclinical benefit in HD mice.
BACKGROUND:C2-8 is a small molecule inhibitor of polyglutamine aggregation and can reduce photoreceptor neurodegeneration in a Drosophila model of Huntington's disease (HD). Further preclinical studies have shown that oral administration of C2-8 in R6/2 HDtransgenic mice can penetrate into the brain, reduce mHTT-exon1 aggregation, improve motor performance and diminish striatal neuron atrophy. OBJECTIVE: In this independent preclinical study, we aimed to evaluate the pharmacokinetic properties and therapeutic efficacy of C2-8 intraperitoneal (IP) delivery in the R6/2 HDmouse. METHODS: R6/2 mice were IP injected with low dose C2-8 (10 mg/kg), high dose C2-8 (20 mg/kg), or vehicle twice daily from 3 weeks to 3 months old. Longitudinal behavioral tests (accelerating Rotarod and wire-hang) were performed to evaluate the motor deficits, and neuropathology was measured by unbiased stereology. RESULTS: We confirmed that the compound has good blood-brain-barrier penetration after acute or sub-chronic intraperitoneal delivery. Chronic treatment with C2-8 in R6/2 mice results in a significant reduction of nuclear mHTT aggregate volume in the brains, replicating a key finding of C2-8 as a polyglutamine aggregation inhibitor in vivo. However, by comparing HDmice with C2-8 treatment to those with vehicle treatment, we were unable to demonstrate significant amelioration of motor deficits using Rotarod and wire-hang tests. Moreover, we did not observe improvement in the striatal neurodegenerative pathology, as measured by brain weight, striatal volume, and striatal neuron volume in the C2-8 treated R6/2 mice. CONCLUSIONS: Our study supports the practice of independent preclinical studies for novel molecules in HD therapeutic development and suggests that the use of alternative delivery strategies and full-length HDmouse models are likely needed to further assess whether the aggregate-inhibiting properties of C2-8 can be consistently translated into a preclinical benefit in HDmice.
Authors: Montserrat Arrasate; Siddhartha Mitra; Erik S Schweitzer; Mark R Segal; Steven Finkbeiner Journal: Nature Date: 2004-10-14 Impact factor: 49.962
Authors: Xiaoqian Zhang; Donna L Smith; Anatoli B Meriin; Sabine Engemann; Deborah E Russel; Margo Roark; Shetia L Washington; Michele M Maxwell; J Lawrence Marsh; Leslie Michels Thompson; Erich E Wanker; Anne B Young; David E Housman; Gillian P Bates; Michael Y Sherman; Aleksey G Kazantsev Journal: Proc Natl Acad Sci U S A Date: 2005-01-10 Impact factor: 11.205
Authors: Vanita Chopra; Jonathan H Fox; Greg Lieberman; Kathryn Dorsey; Wayne Matson; Peter Waldmeier; David E Housman; Aleksey Kazantsev; Anne B Young; Steven Hersch Journal: Proc Natl Acad Sci U S A Date: 2007-10-09 Impact factor: 11.205
Authors: Michelle Gray; Dyna I Shirasaki; Carlos Cepeda; Véronique M André; Brian Wilburn; Xiao-Hong Lu; Jifang Tao; Irene Yamazaki; Shi-Hua Li; Yi E Sun; Xiao-Jiang Li; Michael S Levine; X William Yang Journal: J Neurosci Date: 2008-06-11 Impact factor: 6.167
Authors: Liliana Menalled; Bassem F El-Khodor; Monica Patry; Mayte Suárez-Fariñas; Samantha J Orenstein; Benjamin Zahasky; Christina Leahy; Vanessa Wheeler; X William Yang; Marcy MacDonald; A Jennifer Morton; Gill Bates; Janet Leeds; Larry Park; David Howland; Ethan Signer; Allan Tobin; Daniela Brunner Journal: Neurobiol Dis Date: 2009-05-21 Impact factor: 5.996
Authors: Liliana B Menalled; Andrea E Kudwa; Sam Miller; Jon Fitzpatrick; Judy Watson-Johnson; Nicole Keating; Melinda Ruiz; Richard Mushlin; William Alosio; Kristi McConnell; David Connor; Carol Murphy; Steve Oakeshott; Mei Kwan; Jose Beltran; Afshin Ghavami; Dani Brunner; Larry C Park; Sylvie Ramboz; David Howland Journal: PLoS One Date: 2012-12-20 Impact factor: 3.240
Authors: Sebastian Hofer; Katharina Kainz; Andreas Zimmermann; Maria A Bauer; Tobias Pendl; Michael Poglitsch; Frank Madeo; Didac Carmona-Gutierrez Journal: Front Mol Neurosci Date: 2018-09-04 Impact factor: 6.261